Active influenza vaccine safety surveillance: Potential within a healthcare claims environment

Medical Care

Volumn 47, Issue 12, 2009, Pages 1251-1257

  Brown, Jeffrey S ^a,b   Moore, Kristen M ^a,b   Braun, M Miles ^c   Ziyadeh, Najat ^d   Chan, K Arnold ^d,e   Lee, Grace M ^a,f   Kulldorff, Martin ^a   Walker, Alexander M ^f,g   Platt, Richard ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b HMO Research Network Center for Education and Research in Therapeutics   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d i3 Drug Safety   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g World Health Information Science Consultants LLC   (United States)

Author keywords

Active vaccine safety surveillance; MaxSPRT; Pandemic influenza; Sequential analysis; Vaccine adverse events

Indexed keywords

INFLUENZA VACCINE;

ADOLESCENT; ADULT; AGED; ANAPHYLAXIS; ANGIONEUROTIC EDEMA; ARTICLE; ATAXIA; CHILD; CRANIAL NEUROPATHY; DEMYELINATING DISEASE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; FEMALE; GUILLAIN BARRE SYNDROME; HEALTH INSURANCE; HUMAN; INFANT; INFLUENZA; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MENINGITIS; MENINGOENCEPHALITIDES; NEWBORN; PANDEMIC; PARALYSIS; PERIPHERAL NEUROPATHY; RETROSPECTIVE STUDY; SEIZURE; URTICARIA; INSURANCE; METHODOLOGY; MIDDLE AGED; POSTMARKETING SURVEILLANCE; PRESCHOOL CHILD; STATISTICS;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFLUENZA VACCINES; INSURANCE CLAIM REVIEW; MALE; MIDDLE AGED; PRODUCT SURVEILLANCE, POSTMARKETING; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 73349110088     PISSN: 00257079     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLR.0b013e3181b58b5c     Document Type: Article

References (34)

1. Centers for Disease Control and Prevention. Swine influenza A (H1N1) infection in two children-Southern California, March-April 2009. Morb Mortal Wkly Rep. 2009; 58(dispatch) 1-3.
2. Centers for Disease Control and Prevention. Novel influenza A (H1N1) virus infections-Worldwide, May 6, 2009 [update]. Morb Mortal Wkly Rep. 2009; 58: 453-458.
3. Centers for Disease Control and Prevention. Investigation of Avian Influenza (H5N1) outbreak in humans-Thailand, 2006. Morb Mortal Wkly Rep. 2006; 55(suppl 1): 3-6.
4. U.S. Food and Drug Administration. FDA Approves First US Vaccine for Humans Against the Avian Influenza Virus H5N1. Available at: http:// www.fda.gov/bbs/topics/news/2007/new01611.html. Accessed Feb 6, 2008.
5. Institute of Medicine. The future of drug safety: promoting and protecting the health of the public. In: Committee on the Assessment of the US Drug Safety System; 2006; Washington, DC.
6. Centers for Disease Control and Prevention. Suspension of rotavirus vaccine after reports of intussusception-United States, 1999. Morb Mortal Wkly Rep. 2004; 53: 786-789.
7. Piazza-Hepp TD, Kennedy DL. Reporting of adverse events to Med-Watch. Am J Health Syst Pharm. 1995;52:1436-1439.
8. Brewer T, Colditz GA. Postmarketing surveillance and adverse drug reactions: current perspectives and future needs. JAMA. 1999;281:824-829.
9. Centers for Disease Control and Prevention, Vaccine Safety Datalink. Available at: http://www.cdc.gov/vaccinesafety/vsd/.
10. DeStefano F. The Vaccine Safety Datalink project. Pharmacoepidemiol Drug Saf. 2001;10:403-406.
11. Centers for Disease Control and Prevention. Recommendations from the Advisory Committee on Immunization Practices (ACIP) regarding administration of combination MMRV vaccine [update]. Morb Mortal Wkly Rep 2008; 57: 258-260.
12. Klein N. Vaccine Safety Datalink project: Evaluation of MMRV and febrile seizures. Paper presented at: Advisory Committee on Immunization Practices meeting; February 27, 2008; Atlanta, GA.
13. Lieu T. Rapid cycle analysis for early detection of vaccine adverse events. Paper presented at: The Advisory Committee on Immunization Practices meeting; February 27, 2008; Atlanta, GA.
14. Lieu TA, Kulldorff M, Davis RL, et al. Real-time vaccine safety surveillance for the early detection of adverse events. Med Care. 2007; 45:S89-S95.
15. Davis RL, Kolczak M, Lewis E, et al. Active surveillance of vaccine safety: a system to detect early signs of adverse events. Epidemiology. 2005;16:336-341.
16. Davis R Lewis N, Kulldorff M, et al. Rapid cycle analysis of vaccine safety data. Paper presented at: The Vaccine Safety Datalink annual meeting; April 20, 2005; Redondo Beach, CA.
17. Brown JS, Kulldorff M, Chan KA, et al. Early detection of adverse drug events within population-based health networks: application of sequential testing methods. Pharmacoepidemiol Drug Saf. 2007;16:1275-1284.
18. Velentgas P, Bohn RL, Brown JS, et al. A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine study. Pharmacoepidemiol Drug Saf. 2008;17:1226-1234.
19. France EK, Glanz JM, Xu S, et al. Safety of the trivalent inactivated influenza vaccine among children: a population-based study. Arch Pe-diatr Adolesc Med. 2004;158:1031-1036.
20. Haber P, DeStefano F, Angulo FJ, et al. Guillain-Barré syndrome following influenza vaccination. JAMA. 2004;292:2478-2481.
21. Juurlink DN, Stukel TA, Kwong J, et al. Guillain-Barré syndrome after influenza vaccination in adults: a population-based study. Arch Intern Med. 2006;166:2217-2221.
22. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med. 1998;339:1797-1802.
23. McMahon AW, Iskander J, Haber P, et al. Adverse events after inactivated influenza vaccination among children less than 2 years of age: analysis of reports from the vaccine adverse event reporting system, 1990-2003. Pediatrics. 2005;115:453-460.
24. Zhou W, Pool V, DeStefano F, et al. A potential signal of Bell's palsy after parenteral inactivated influenza vaccines: reports to the Vaccine Adverse Event Reporting System (VAERS)-United States, 1991-2001. Pharmacoepidemiol Drug Saf. 2004;13:505-510.
25. Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA. 2005;294:2720-2725.
26. Belshe R, Lee MS, Walker RE, et al. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines. 2004;3:643-654. (Pubitemid 39576751)
27. Fiore AE, Shay DK, Haber P, et al. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007. Recomm Rep. 2007;56(RR-6):1-54.
28. Kulldorff M DR, Kolczak M, Lewis E, et al. A maximized sequential probability ratio test for drug and vaccine safety surveillance (working paper, 2008). Available at: http://www.dacp.org/faculty-Kulldorff.html.
29. Bohlke K Davis RL, Marcy SM, et al. Risk of anaphylaxis after vaccination of children and adolescents. Pediatrics. 2003;112:815-820.
30. Hambidge SJ, Glanz JM, France EK, et al. Safety of trivalent inactivated influenza vaccine in children 6 to 23 months old. JAMA. 2006;296: 1990-1997.
31. Brown JS, Lee G, Velentgas P, et al. Reliability of ICD-9 Coding for Same Day Adverse Event Identification: Assessment of the Temporal Relationship Between Acute and Chronic Urticaria Events and Influenza Vaccination Via Medical Chart Review in an Outpatient Setting. Report to the US Food and Drug Administration, Contract No. HHSF 223200710017C; 2008.
32. Moore K, Andrade S, Cassidy-Bushrow A, et al. Variation in ICD-9 diagnosis coding within and across health systems. Paper presented at: The International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 14th Annual International Meeting; May 18, 2009; Orlando, FL.
33. Burwen DR, LaVoie L, Braun MM, et al. Evaluating adverse events after vaccination in the Medicare population. Pharmacoepidemiol Drug Saf. 2007;16:753-761.
34. Moore KM, Duddy A, Braun MM, et al. Potential population-based electronic data sources for rapid pandemic influenza vaccine adverse event detection: a survey of health plans. Pharmacoepidemiol Drug Saf. 2008;17:1137-1141.